XML 26 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Schedule of Diluted Net (Loss) Income Per Common Share

The Company calculates net income (loss) per common share in accordance with ASC 260, Earnings Per Share. Basic net income (loss) per common share for the three months ended March 31, 2024 and 2023 was determined by dividing net income (loss) applicable to common stockholders by the weighted average number of common shares outstanding during the period. Per ASC 260, Earnings Per Share, the weighted average number of common shares outstanding utilized for determining the basic net income (loss) per common share for the three months ended March 31, 2024 includes the outstanding prefunded warrants to purchase 7,516,267 and 3,200,000 shares of common stock issued in the April 2022 public offering and December 2020 public offering, respectively. The outstanding prefunded warrants to purchase 11,303,667 and 3,200,000 shares of common stock issued in the April 2022 public offering and December 2020 public offering were included in the three months ended March 31, 2023, respectively. Diluted net income (loss) per common share for the three months ended March 31, 2024 and 2023 was determined as follows (in thousands, except share and per share amounts):

 

Three Months Ended March 31,

 

 

2024

 

 

2023

 

Net income (loss) allocated to common shares

$

411

 

 

$

(33,876

)

 

 

 

 

 

Weighted average common shares outstanding – basic

 

48,245,559

 

 

 

47,757,246

 

Dilutive effect of restricted stock units

 

319,492

 

 

 

 

Weighted average common shares outstanding – diluted

 

48,565,051

 

 

 

47,757,246

 

 

 

 

 

 

Net income (loss) per share – diluted

$

0.01

 

 

$

(0.71

)

 

Summary of Antidilutive Securities Excluded from Computation of Weighted Average Common Stock and Outstanding Restricted Stock Units

The following potentially dilutive shares of common stock and outstanding restricted stock units that contain certain performance contingencies have not been included in the computation of diluted net income (loss) per share for the three months ended March 31, 2024 and 2023, as the result would be anti-dilutive or the performance contingencies have not been met:

 

Three Months Ended March 31,

 

 

2024

 

 

2023

 

Outstanding stock options

 

2,716,602

 

 

 

1,931,389

 

Outstanding restricted stock units

 

600,000

 

 

 

2,214,490

 

Warrants to purchase common stock associated with December 2020 public offering - Series 2

 

6,800,000

 

 

 

6,800,000

 

Warrants to purchase common stock associated with April 2022 public offering

 

15,000,000

 

 

 

15,000,000

 

Warrants to purchase common stock associated with Loan Agreement

 

198,811

 

 

 

198,811

 

Common stock associated with March 2019 Notes

 

1,138,200

 

 

 

1,138,200

 

Warrants to purchase common stock associated with Danforth

 

50,000

 

 

 

50,000

 

Total

 

26,503,613

 

 

 

27,332,890